153 related articles for article (PubMed ID: 21923429)
21. Efficacy of a pill-swallowing training intervention to improve antiretroviral medication adherence in pediatric patients with HIV/AIDS.
Garvie PA; Lensing S; Rai SN
Pediatrics; 2007 Apr; 119(4):e893-9. PubMed ID: 17353298
[TBL] [Abstract][Full Text] [Related]
22. Determinants of nontraditional therapy use in patients with HIV infection. A prospective study.
Singh N; Squier C; Sivek C; Nguyen MH; Wagener M; Yu VL
Arch Intern Med; 1996 Jan; 156(2):197-201. PubMed ID: 8546553
[TBL] [Abstract][Full Text] [Related]
23. Drug interactions between psychoactive substances and antiretroviral therapy in individuals infected with human immunodeficiency and hepatitis viruses.
Neuman MG; Monteiro M; Rehm J
Subst Use Misuse; 2006; 41(10-12):1395-463. PubMed ID: 17002989
[TBL] [Abstract][Full Text] [Related]
24. Devolving of statin prescribing to general practitioners for HIV-infected patients receiving antiretroviral therapy.
Benn PD; Miller RF; Evans L; Minton J; Edwards SG
Int J STD AIDS; 2009 Mar; 20(3):202-4. PubMed ID: 19255272
[TBL] [Abstract][Full Text] [Related]
25. Triple-class HIV antiretroviral therapy failure in an Australian primary care setting.
Bloch M; Farris M; Tilden D; Gowers A; Cunningham N
Sex Health; 2010 Mar; 7(1):17-24. PubMed ID: 20152091
[TBL] [Abstract][Full Text] [Related]
26. Prevalence of potential drug-drug interactions involving antiretroviral drugs in a large Kenyan cohort.
Kigen G; Kimaiyo S; Nyandiko W; Faragher B; Sang E; Jakait B; Owen A; Back D; Gibbons S; Seden K; Khoo SH;
PLoS One; 2011 Feb; 6(2):e16800. PubMed ID: 21373194
[TBL] [Abstract][Full Text] [Related]
27. Human immunodeficiency virus in an aging population, a complication of success.
Kirk JB; Goetz MB
J Am Geriatr Soc; 2009 Nov; 57(11):2129-38. PubMed ID: 19793157
[TBL] [Abstract][Full Text] [Related]
28. Antiretroviral induced adverse drug reactions in Iranian human immunodeficiency virus positive patients.
Khalili H; Dashti-Khavidaki S; Mohraz M; Etghani A; Almasi F
Pharmacoepidemiol Drug Saf; 2009 Sep; 18(9):848-57. PubMed ID: 19551698
[TBL] [Abstract][Full Text] [Related]
29. Outcomes of human immunodeficiency virus-infected and -exposed children undergoing surgery--a prospective study.
Karpelowsky JS; Leva E; Kelley B; Numanoglu A; Rode H; Millar AJ
J Pediatr Surg; 2009 Apr; 44(4):681-7. PubMed ID: 19361626
[TBL] [Abstract][Full Text] [Related]
30. Role of antiretroviral therapies in mucocutaneous manifestations in HIV-infected children over a period of two decades.
Seoane Reula E; Bellon JM; Gurbindo D; Muñoz-Fernandez MA
Br J Dermatol; 2005 Aug; 153(2):382-9. PubMed ID: 16086754
[TBL] [Abstract][Full Text] [Related]
31. Human immunodeficiency virus-associated squamous cell cancer of the anus: epidemiology and outcomes in the highly active antiretroviral therapy era.
Chiao EY; Giordano TP; Richardson P; El-Serag HB
J Clin Oncol; 2008 Jan; 26(3):474-9. PubMed ID: 18202423
[TBL] [Abstract][Full Text] [Related]
32. Greater effect of highly active antiretroviral therapy on survival in people aged > or =50 years compared with younger people in an urban observational cohort.
Perez JL; Moore RD
Clin Infect Dis; 2003 Jan; 36(2):212-8. PubMed ID: 12522755
[TBL] [Abstract][Full Text] [Related]
33. [Epidemiology of primary drug resistance in chronically HIV-infected patients in Nordrhein-Westfalen, Germany, 2001-2005].
Oette M; Kaiser R; Däumer M; Fätkenheuer G; Rockstroh JK; Knechten H; Mitrenga D; Beerenwinkel N; Sagir A; Pfister H; Häussinger D
Dtsch Med Wochenschr; 2007 May; 132(18):977-82. PubMed ID: 17457780
[TBL] [Abstract][Full Text] [Related]
34. Lipid-lowering efficacy and safety after switching to atazanavir-ritonavir-based highly active antiretroviral therapy in patients with human immunodeficiency virus.
Nguyen ST; Eaton SA; Bain AM; Rahman AP; Payne KD; Bedimo R; Herrington JD; Maclayton DO; Rodriguez-Barradas MC; Busti AJ
Pharmacotherapy; 2008 Mar; 28(3):323-30. PubMed ID: 18294112
[TBL] [Abstract][Full Text] [Related]
35. Acute pancreatitis associated with different combination therapies in patients infected with human immunodeficiency virus.
Guo JJ; Jang R; Louder A; Cluxton RJ
Pharmacotherapy; 2005 Aug; 25(8):1044-54. PubMed ID: 16207094
[TBL] [Abstract][Full Text] [Related]
36. Potential drug-drug interactions in HIV-infected children on antiretroviral therapy in Lagos, Nigeria.
Oshikoya KA; Oreagba IA; Lawal S; Awodele O; Ogunleye OO; Senbanjo IO; Olayemi SO; Ezeaka VC; Temiye EO; Adeyemo TA; Opanuga O; Lesi OA; Akanmu SA
HIV AIDS (Auckl); 2014; 6():49-59. PubMed ID: 24741328
[TBL] [Abstract][Full Text] [Related]
37. Lipodystrophy and dyslipidemia in human immunodeficiency virus-infected Thai patients receiving antiretroviral therapy.
Chuapai Y; Kiertiburanakul S; Malathum K; Sungkanuparph S
J Med Assoc Thai; 2007 Mar; 90(3):452-8. PubMed ID: 17427520
[TBL] [Abstract][Full Text] [Related]
38. The incidence of potential interactions between dietary supplements and prescription medications in cancer patients at a Veterans Administration Hospital.
Lee AH; Ingraham SE; Kopp M; Foraida MI; Jazieh AR
Am J Clin Oncol; 2006 Apr; 29(2):178-82. PubMed ID: 16601439
[TBL] [Abstract][Full Text] [Related]
39. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
Van Vaerenbergh K
Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
[TBL] [Abstract][Full Text] [Related]
40. Exfoliative dermatitis: patterns of clinical presentation in a tropical rural and suburban dermatology practice in Nigeria.
Salami TA; Enahoro Oziegbe O; Omeife H
Int J Dermatol; 2012 Sep; 51(9):1086-9. PubMed ID: 22909364
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
